Clinical Trial Search

Primary: Number of Patients With ST-segment Elevation Resolution Equal or More Than 50% — 47; 51 participants — p=0.56

Primary: Number of Participants With Complete Sum ST Resolution (STR) 60 Minutes (Min) After Percutaneous Coronary Intervention (PCI) (Per Protocol Population) — 71; 65…

Primary: Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint) — 143; 145 patients — p=0.8214

Primary: All Cause Mortality and Readmission at 30 Days. — 16; 28 participants — p=<0.05

Primary: Rate of Complete ST-segment Elevation Resolution at 60 Minutes After the End of the Procedure — 38; 58 Participants

Primary: Percentage of Sites With Reduction in Door to Balloon Time — 83; 50 percentage of sites with improved D2B

Primary: The Composite Incidence of Death and Non-coronary Artery Bypass Graft (CABG) Major Bleeding — 5.1; 8.5 percentage of participants — p=0.0014

Primary: Platelet Reactivity by VerifyNow P2Y12 — 188; 125; 228 PRU — p=0.017

Primary: Short-termed Fractal Scaling Exponent (Alpha 1) — 0.01; -0.03 unit-less — p=0.34

Primary: Infarct Size on Baseline Cardiac Magnetic Resonance Imaging (cMRI) — 20.1; 21.0 ml — p=0.90

Primary: Successful Reperfusion — 305; 149 Participants — p=0.05

Primary: Global Infarct Size — 5.453; 8.598; 9.004; 7.819 Percentage of global infarct size

Primary: Mortality at 30 Days — 1; 7; 3; 2 participants

Primary: Platelet Reactivity Measured by VerifyNow PRU — 63; 214 P2Y12 reaction units (PRU) — p=<0.001

Primary: Arrhythmias of Interest, 48 Hours (Overall) — 0; 0; 0; 0 participants

Primary: Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS. — 116; 135…

Primary: Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion — 15.1; 17.9; 17.2 Percentage of Left…

Primary: Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™ — 98.4; 257.5 PRU…

Primary: The Percentage of Participants With Occurrence of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Urgent Revascularization (UR), or Glycoprotein (GP)…

Primary: Final Infarct Size — 5; 6 % of LV

Primary: 30-day Composite Major Adverse Cardiac Event (MACE) — 256; 83 participants

Primary: Imaging Outcome (Powered): Minimal Stent Area (MSA) — 5.72; 5.36 mm^2 — p=<0.0001

Primary: P2Y12 Reaction Units (PRU) — 95; 164 PRU — p=0.022

Primary: Composite of Death, Myocardial (re-) Infarction, or Stroke — 153; 163 participants — p=0.15

Primary: Peri-Procedural Myocardial Injury — 23; 29 Participants

Primary: Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by Verify Now Point of Care Assay and Expressed as P2Y12 Reaction Units (PRU) — 270.23; 247.73…

Primary: Postinfarct Remodeling — 11; 6 Number of participants with remodeling

Primary: Number of Participants With the Composite Endpoint of MACCE — 23; 121 Participants — p=<0.001

Primary: Number of Participants With a Change in high-on Treatment Platelet Reactivity (HPR) — 37; 33; 24; 0 count of participants

Primary: Area Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB) — 6582.0; 6738.3; 5252.2; 5471.9 ng*hr/mL